Teva Pharmaceutical Industries (TEVA) Reports Q1 Earnings: What Key Metrics Have to Say

Core Insights - Teva Pharmaceutical Industries Ltd. reported $3.89 billion in revenue for Q1 2025, a year-over-year increase of 1.9% and an EPS of $0.52, up from $0.48 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $3.97 billion by 1.92%, while the EPS exceeded the consensus estimate of $0.47 by 10.64% [1] Financial Performance - Teva's shares have returned +18.6% over the past month, outperforming the Zacks S&P 500 composite's +10.6% change [3] - The company currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3] Geographic Revenue Breakdown - United States: Revenue of $1.91 billion, exceeding the average estimate of $1.87 billion, with a year-over-year change of +10.7% [4] - Europe: AJOVY generated $58 million, slightly above the average estimate of $56.74 million, reflecting a +13.7% year-over-year change [4] - International Markets: COPAXONE revenue was $10 million, below the estimate of $10.67 million, representing a -16.7% change year-over-year [4] - Generic products in International Markets generated $468 million, slightly below the estimate of $487.47 million, with a -1.9% year-over-year change [4] - Europe: COPAXONE revenue was $42 million, below the estimate of $43.68 million, indicating a -26.3% year-over-year change [4] - Europe: Generic products revenue was $989 million, slightly below the estimate of $991.61 million, with a -1.5% year-over-year change [4] - Europe: Other products generated $50 million, significantly below the estimate of $95.70 million, reflecting a -46.8% year-over-year change [4] - Europe: Respiratory products revenue was $55 million, below the estimate of $60.84 million, indicating a -16.7% year-over-year change [4] - International Markets: Other products generated $61 million, below the estimate of $94.61 million, representing a -33% year-over-year change [4] - Total revenue from COPAXONE was $106 million, exceeding the estimate of $84.97 million, with a +7.1% year-over-year change [4] - API sales to third parties amounted to $130 million, surpassing the estimate of $115.17 million, reflecting a +1.6% year-over-year change [4]